NDANASALSPRAY, METERED
Approved
Jun 2020
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
5/8 — Partial
GIMOTI (metoclopramide hydrochloride) by Pfizer is gastric, biliary, or pancreatic secretions. First approved in 2020.
Drug data last refreshed 16h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
GIMOTI is a nasal spray formulation of metoclopramide hydrochloride, a prokinetic agent approved by the FDA in 2020. It enhances gastric motility by sensitizing tissues to acetylcholine, accelerating gastric emptying and intestinal transit. The drug is indicated for gastroesophageal reflux disease, diabetic gastroparesis, and related GI motility disorders.
$0.003BPart D
Peak12.3 years to LOEProduct is in peak commercial phase with modest Medicare uptake (1,457 Part D claims, $3M spending in 2023), suggesting a niche market opportunity with lean organizational structure.
Mechanism of Action
gastric, biliary, or pancreatic secretions. The exact mechanism of action of metoclopramide in the treatment of gastroesophageal reflux and acute and recurrent diabetic gastroparesis has not been fully established. It seems to sensitize tissues to the action of acetylcholine. The effect of…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
GIMOTI is a niche branded product with modest commercial scale ($3M Part D spending) and no active clinical pipeline, limiting traditional career mobility and advancement velocity. Professionals joining this team should expect a smaller, focused organization with emphasis on payer management, MSL activities, and specialist sales rather than large-scale commercial expansion.
Worked on GIMOTI at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.